Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

(2014) PA Kaufman et al.   CANCER RESEARCH

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

(2012) F. Andre et al.   ANNALS OF ONCOLOGY

Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy

(2012) J.P.M. Ayoub et al.   Current Oncology

Fuel, electricity, ER and HER2—a hybrid-car model of breast cancer

(2012) Shigehira Saji et al.   Nature Reviews Clinical Oncology

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?

(2011) Philippe Aftimos et al.   ADVANCES IN THERAPY

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

(2011) K. Aogi et al.   ANNALS OF ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Eribulin mesylate in patients with refractory cancers: a Phase I study

(2011) Toru Mukohara et al.   INVESTIGATIONAL NEW DRUGS

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) F. Cardoso et al.   ANNALS OF ONCOLOGY

Advances in therapy: eribulin improves survival for metastatic breast cancer

(2010) Patrick G. Morris   ANTI-CANCER DRUGS

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs

(2008) Neil Ashley et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS